BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Biogen Abandons Aduhelm Study Following Low Patient Enrollment

  Biogen indicated it has terminated an observational study of its approved Alzheimer’s drug Aduhelm after only 29 people signed up for an expected enrollment of 6,000 patients.

  June 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  BUSM Researchers Gain Insight into Key Genetic Driver of Alzheimer’s

  The Boston University School of Medicine has unraveled details about a known genetic component for the development of Alzheimer’s disease (AD): the APOE4 gene.

  June 24, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Clinical Catch-Up: xBiotech, Exelixis, DermBiont Target Cancer

  While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.

  June 24, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Emergent, Astellas & More Submit New Applications to FDA

  With the submission of NDAs and BLAs, multiple companies are bidding for regulatory approval of drug candidates. BioSpace takes a look at several of the latest requests.

  June 24, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  RedHill Axes 1/3 of US Workforce in 18-Month Frugality Plan

  RedHill announced that it will lay off a third of its U.S. workforce in an effort to save money over the next year and a half.

  June 24, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Serious Safety Signal Slows Sarepta’s MOMENTUM in DMD Trial

  Sarepta announced that the FDA has put the Phase II trial for its SRP-5051 (vesleteplirsen) for the treatment of patients with DMD on clinical hold following a serious safety signal.

  June 24, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Mask On: Researchers Engineer “Masked” IL-12 Treatment to Fight Cancer

  Researchers and drug developers have searched for a way to deliver IL-12 to patients. Researchers at the University of Chicago’s Pritzker School of Molecular Engineering may have found one.

  June 24, 2022

   · 

  5 min read

   · 

  Hayley Shasteen
• 

  Deals

  PwC Projects ‘Flurry of Deals’ Across Life Science Industry

  A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”

  June 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Xenotransplant Patient’s New Heart Doubled in Size, Autopsy Shows

  The genetically-modified heart of a man who died two months after his heart was replaced with that of a pig had nearly doubled in size, autopsy results show.

  June 24, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Job Trends

  Breaking Ground & Leaving Town: June Brings Job Creations, Layoffs for Life Sciences

  The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.

  June 24, 2022

   · 

  3 min read

   · 

  Rosemary Scott